EPOCH
Sponsors
National Cancer Institute (NCI)
Conditions
AIDS Related LymphomaAIDS-Associated LymphomaDiffuse Large B-Cell LymphomaHodgkin LymphomaLymphoma, AIDS-relatedLymphoma, Extranodal NK-T-CellLymphoma, Large B-Cell, DiffuseLymphoma, Mantle Cell
Phase 2
EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma
CompletedNCT00001563
Start: 1997-01-08End: 2005-05-05Updated: 2022-01-19
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
CompletedNCT00006436
Start: 2001-01-29End: 2024-01-18Updated: 2025-12-30
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
CompletedNCT00069238
Start: 2003-09-19End: 2021-03-17Updated: 2022-02-24
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
CompletedNCT00114738
Start: 2005-06-15End: 2022-08-11Updated: 2022-10-10
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
CompletedNCT01030900
Start: 2009-10-22End: 2021-08-06Updated: 2022-10-06